NIT’s lead product is NT-I7
, an engineered T cell amplifier designed to reconstitute and enhance antitumoral T cell immunity. NT-I7
consists of homodimeric Interleukin-7 (IL-7) molecules, which are homeostatic cytokines that enhance the number and function of T cells, biologically fused to IgD/IgG4 immunoglobulin domain (hyFc®) as a safe and effective long-acting carrier.
NIT is currently conducting multiple clinical trials of NT-I7
,aiming at developing it as not only a first-in-class treatment of lymphopenia as a monotherapy, but also a breakthrough “enabling” drug to enhance cancer immunotherapeutics, which may substantially enhance the anti-tumor efficacy of the conventional cancer treatments and/or novel immunotherapies harnessing T cell immunity as a combination therapy.
Based in Rockville, Maryland, NIT has the core competency of global clinical development and business development actively networking with many global leading research and development organizations.